Related Experiment Video

Updated: Aug 14, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Telomerase activity, Myc and Bcl-2: possible indicators of effective therapy of prostate cancer with

D Chatterjee1, J H Wyche, D P Romero

  • 1Department of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, RI 02912, USA.

Anticancer Research
|November 4, 2000
PubMed

Insights

This study shows that 9-nitrocamptothecin (9NC) reduces telomerase activity and c-Myc/Bcl-2 expression in prostate tumors. These markers may indicate 9NC treatment effectiveness.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Prostate cancer is a leading cause of mortality in men.
  • 9-nitrocamptothecin (9NC) is a chemotherapeutic agent with potential in cancer treatment.
  • Understanding molecular mechanisms of drug response is crucial for effective cancer therapy.

Purpose of the Study:

  • To investigate the molecular changes associated with 9-nitrocamptothecin (9NC) treatment in human prostate tumors.
  • To identify potential biomarkers for predicting 9NC efficacy.

Main Methods:

  • Xenograft model using human DU145 prostate cancer cells in immunodeficient mice.
  • Administration of 9-nitrocamptothecin (9NC).
  • Measurement of telomerase activity, c-Myc, and Bcl-2 expression levels.

Main Results:

  • 9-nitrocamptothecin (9NC) treatment led to down-regulation of telomerase activity and c-Myc and Bcl-2 expression.
  • These molecular changes were observed in sensitive tumors but not in 9NC-resistant tumors.
  • Down-regulation correlated with tumor regression.

Conclusions:

  • Telomerase activity, c-Myc, and Bcl-2 expression serve as indicators of 9NC treatment effectiveness in prostate cancer.
  • These markers could be valuable for monitoring therapeutic response.
  • Further research may validate these biomarkers in clinical settings.

More Related Videos

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...